Novel Fgfr3 Fusion Product

Patent No. EP2824181 (titled "Novel Fgfr3 Fusion Product") was filed by Astellas Pharma on Mar 7, 2013. The application was issued on Nov 14, 2018.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOULT WADE TENNANTAug 14, 2019BOULT WADE TENNANT
JAMES POOLEAug 12, 2019CARPMAELS & RANSFORD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2824181

ASTELLAS PHARMA
Application Number
EP13757006A
Filing Date
Mar 7, 2013
Status
Revoked
May 26, 2023
Publication Date
Nov 14, 2018